Genesis HealthCare (GEN) Reports In-Line Q2 EPS, provides guidance

Genesis HealthCare (NASDAQ: GEN) reported Q2 EPS of $0.54, in-line with the analyst estimate of $0.54. Revenue for the quarter came in at $974 million versus the consensus estimate of $970.01 million.

GUIDANCE:

Genesis HealthCare sees FY2025 EPS of $2.18-$2.23, versus the consensus of $2.21. Genesis HealthCare sees FY2025 revenue of $3.905-3.93 billion, versus the consensus of $3.913 billion.

For earnings history and earnings-related data on Genesis HealthCare (GEN) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Nvidia develops 6G radio chip as data center shifts stay on track - Jefferies
• Fermi files statement opposing former CEO's shareholder meeting proposal